Tolerogenic vaccines for multiple sclerosis
Mannie, Mark D.; Curtis, Alan D. II
Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized in the generation of tolerogenic vaccines that inhibit experimental autoimmune encephalomyelitis in a preclinical setting, and these vaccines may be a prequel of the tolerogenic vaccines that may have therapeutic benefit in Multiple Sclerosis. The purpose here is to provide a snapshot of the current concepts and future prospects of tolerogenic vaccination for Multiple Sclerosis, along with the central challenges to clinical application.
Mannie, Mark D., & Curtis, Alan D. II. (January 2013). Tolerogenic vaccines for multiple sclerosis. Hum Vaccin Immunother, (9:5), p.1032–1038. Retrieved from http://hdl.handle.net/10342/7818
Mannie, Mark D., and Curtis, Alan D. II. "Tolerogenic vaccines for multiple sclerosis". Hum Vaccin Immunother. 9:5. (1032–1038.), January 2013. September 29, 2020. http://hdl.handle.net/10342/7818.
Mannie, Mark D. and Curtis, Alan D. II, "Tolerogenic vaccines for multiple sclerosis," Hum Vaccin Immunother 9, no. 5 (January 2013), http://hdl.handle.net/10342/7818 (accessed September 29, 2020).
Mannie, Mark D., Curtis, Alan D. II. Tolerogenic vaccines for multiple sclerosis. Hum Vaccin Immunother. January 2013; 9(5) 1032–1038. http://hdl.handle.net/10342/7818. Accessed September 29, 2020.